NewEdge Advisors’s Adicet Bio ACET Stock Holding History

NewEdge Advisors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,854	Closed	-$26.2K	–	4180
2026 Q1	$26.2K	Buy	+3,854	New	+$28.8K	﹤0.01%	3121

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

NewEdge Advisors's ACET Position: Q2 2026 in Review

NewEdge Advisors sold out of Adicet Bio (ACET) in Q2 2026, closing a stake of 3,854 shares — an estimated $26.2K sold.

NewEdge Advisors first reported a position in ACET in Q1 2026 and held it in 1 quarter. The position peaked at $26.2K in Q1 2026. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

NewEdge Advisors reported no remaining Adicet Bio position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 3,854 Adicet Bio shares in Q2 2026, an estimated $26.2K.
NewEdge Advisors first reported a position in Adicet Bio in Q1 2026 and held it in 1 quarter.
NewEdge Advisors's Adicet Bio position peaked at $26.2K in Q1 2026.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.